FindTrial
Sign In

A multi-center clinical study on treatment of severe neuroimmune diseases with short-term blood purification and sequential reduction of intravenous immunoglobulin

A multi-center clinical study on treatment of severe neuroimmune diseases with short-term blood purification and sequential reduction of intravenous immunoglobulin

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200060874
Enrollment
Unknown
Registered
2022-06-13
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroimmune disease

Interventions

The group receiving short-range blood purification and sequential reduction of IVIG:The group receiving IVIG alone

Sponsors

The central hospital of Dalian
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-80; 2. anti-AchR antibody (main pathogenic antibody of MG), anti-ganglioside antibody (pathogenic antibody of GBS) positive; 3. MG crisis and severe GBS within 48 hours, open airway required to assist ventilation.

Exclusion criteria

Exclusion criteria: 1.Patients with cholinergic crisis; 2.MG crisis with anti-Musk antibody and anti-LRP4 antibody as pathogenic antibodies; ganglioside antibody-negative GBS; 3.blood purification>=3times.

Design outcomes

Primary

MeasureTime frame
Anti-AchR antibody;ganglioside antibody;complement;blood gas;cytokine;—

Countries

China

Contacts

Public ContactHengjie Zhou
13504250523@163.com+86 13504250453

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026